QCG
CMPX icon

Quadrant Capital Group’s Compass Therapeutics CMPX Stock Holding History

Quadrant Capital Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14K Hold
405
– – ﹤0.01% 2496
2025
Q4 		$2.17K Hold
405
– – ﹤0.01% 2510
2025
Q3 		$1.42K Buy
+405
New +$1.28K ﹤0.01% 2525

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Quadrant Capital Group's CMPX Position: Q1 2026 in Review

Quadrant Capital Group held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 405 shares worth $2.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2496.

Quadrant Capital Group first reported a position in CMPX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.17K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Quadrant Capital Group held 405 shares of Compass Therapeutics worth $2.14K as of Q1 2026.
  • Quadrant Capital Group left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2496 holding.
  • Quadrant Capital Group first reported a position in Compass Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quadrant Capital Group's Compass Therapeutics position peaked at $2.17K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.